{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:22:10Z","timestamp":1791105730061,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,11,4]],"date-time":"2004-11-04T00:00:00Z","timestamp":1099526400000},"content-version":"vor","delay-in-days":2440,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[1998,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In contrast to levodopa (<jats:sc>L<\/jats:sc>\u2010dopa), de novo administration of the D2\u2010like receptor agonist bromocriptine to patients with Parkinson's disease (PD) or to 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine (MPTP)\u2010treated subhuman primates is not associated with the onset of significant dyskinesia. We now compare the ability of the novel D2\u2010like selective dopamine agonist ropinirole with that of bromocriptine and <jats:sc>L<\/jats:sc>\u2010dopa to induce dyskinesia in MPTP\u2010treated common marmosets. MPTP\u2010treated common marmosets were treated with placebo, <jats:sc>L<\/jats:sc>\u2010dopa plus carbidopa, ropinirole, or bromocriptine daily for 30 days (n = 4 per group) in doses that were titrated to similarly increase locomotion and improve motor disability. <jats:sc>L<\/jats:sc>\u2010dopa rapidly induced dyskinesia of moderate to severe intensity, whereas ropinirole and bromocriptine produced mild dyskinesia over the course of the study that was significantly less severe than in the <jats:sc>L<\/jats:sc>\u2010dopa\u2010treated group (p &lt; 0.05). However, in a separate group of marmosets previously primed with <jats:sc>L<\/jats:sc>\u2010dopa to exhibit dyskinesia, ropinirole administration elicited severe dyskinesias comparable with that of <jats:sc>L<\/jats:sc>\u2010dopa in a dosedependent fashion. Ropinirole, in common with bromocriptine, has a lesser tendency than <jats:sc>L<\/jats:sc>\u2010dopa to produce dyskinesia while similarly improving motor performance in drug\u2010naive MPTP\u2010treated marmosets. However, in common with other dopamine agonists, ropinirole will elicit comparable dyskinesia once <jats:sc>L<\/jats:sc>\u2010dopa priming has occurred. These results predict a similar response to ropinirole and other long\u2010acting dopamine agonists in <jats:sc>L<\/jats:sc>\u2010dopa\u2010naive patients with PD and emphasize the importance of avoiding initial dyskinesia induction through early use of dopamine agonist drugs.<\/jats:p>","DOI":"10.1002\/mds.870130207","type":"journal-article","created":{"date-parts":[[2005,5,28]],"date-time":"2005-05-28T20:40:51Z","timestamp":1117312851000},"page":"234-241","source":"Crossref","is-referenced-by-count":183,"title":["De novo administration of ropinirole and bromocriptine induces less dyskinesia than <scp>L<\/scp>\u2010dopa in the MPTP\u2010treated marmoset"],"prefix":"10.1002","volume":"13","author":[{"given":"Ronald K. B.","family":"Pearce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"David Marsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,11,4]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.2.340"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1991.tb05028.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198704000-00007"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198503000-00007"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198409000-00004"},{"key":"e_1_2_1_7_2","first-page":"315","volume-title":"Recent developments in Parkinson's disease","author":"Olanow CW","year":"1985"},{"key":"e_1_2_1_8_2","first-page":"143","article-title":"Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease","volume":"43","author":"Lees AJ","year":"1981","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_1_9_2","first-page":"401","article-title":"Bromocriptine as the first treatment of Parkinson's disease. Long\u2010term results","volume":"138","author":"Rascol A","year":"1982","journal-title":"Rev Neurol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)90783-3"},{"key":"e_1_2_1_11_2","series-title":"Advances in neurology","first-page":"113","volume-title":"Role of selective D1 and D2 agonists in inducing dyskinesia in drug\u2010naive MPTP monkeys","author":"B\u00e9dard PJ","year":"1993"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.1.83"},{"key":"e_1_2_1_13_2","first-page":"509","article-title":"Pergolide in Parkinson's disease","volume":"40","author":"Quinn NP","year":"1984","journal-title":"Adv Neurol"},{"issue":"1","key":"e_1_2_1_14_2","first-page":"P216","article-title":"Cabergoline as single therapy has a sustained antiparkinsonian action with less dyskinesia in MPTP monkeys. [Abstract]","volume":"11","author":"Grondin R","year":"1996","journal-title":"Mov Disord"},{"key":"e_1_2_1_15_2","first-page":"407","article-title":"Dopaminergic ergots in parkinsonism","volume":"37","author":"Agnoli A","year":"1980","journal-title":"Arch Gen Psychiatry"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-3565(25)39350-X","article-title":"Differential effect of selective D1 and D2 dopamine receptor agonists on levodopa\u2010induced dyskinesia in 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine\u2010exposed monkeys","volume":"267","author":"Blanchet P","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0022-3565(25)20396-2","article-title":"Effect of D1 and D2 agonists and antagonists on dyskinesia produced by l\u2010dopa in 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine\u2010treated monkeys","volume":"259","author":"Gomez\u2010Mancilla B","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870100606"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.6.10.949"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110117"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410310514"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4886(92)90125-A"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0022-3565(25)24503-7","article-title":"Continuous adminstration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U\u201091356A) in MPTP\u2010exposed monkeys","volume":"272","author":"Blanchet PJ","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(89)90146-3","article-title":"Treatment of Parkinson's disease with the novel dopamine D2 agonist ropinirole","volume":"1","author":"Kapoon R","year":"1989","journal-title":"Lancet"},{"key":"e_1_2_1_25_2","first-page":"S04.003","article-title":"A double\u2010blind study comparing ropinirole and bromocriptine in patients with early Parkinson's disease. [Abstract]","volume":"46","author":"Korczyn AD.","year":"1996","journal-title":"Neurology"},{"key":"e_1_2_1_26_2","first-page":"S67.003","article-title":"A multicenter double\u2010blind study of ropinirole as an adjunct to l\u2010dopa in Parkinson's disease","volume":"46","author":"Kreider M","year":"1996","journal-title":"Neurology"},{"key":"e_1_2_1_27_2","first-page":"S04.005","article-title":"A double\u2010blind l\u2010dopa controlled study of ropinirole in patients with early Parkinson's disease","volume":"46","author":"Rascol O.","year":"1996","journal-title":"Neurology"},{"key":"e_1_2_1_28_2","first-page":"S04.002","article-title":"The efficacy and safety of ropinirole in early parkinsonian patients not receiving dopaminergic therapy: a multicenter double\u2010blind study","volume":"46","author":"Wheadon D","year":"1996","journal-title":"Neurology"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91855-5"},{"key":"e_1_2_1_30_2","first-page":"93P","article-title":"Ropinirole, a novel dopaminergic agent for the treatment of Parkinson's disease, with selectivity for cloned dopamine D3 receptors","volume":"110","author":"Bowen WP","year":"1993","journal-title":"Br J Pharmacol"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(84)90467-1"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.7.949"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.5.826"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(93)90238-B"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90790-5"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)90667-K"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-0186(92)90248-P"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.890210107"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870050203"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270105"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.1994.tb00584.x"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.8.1545"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-0485-2_41"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.870130207","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.870130207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:10:04Z","timestamp":1760965804000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.870130207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1998,3]]}},"alternative-id":["10.1002\/mds.870130207"],"URL":"https:\/\/doi.org\/10.1002\/mds.870130207","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,3]]}}}